<DOC>
	<DOC>NCT00484419</DOC>
	<brief_summary>A 16 week open-label study with subjects receiving background metformin monotherapy. 150 subjects randomized 1:1:1 to receive 1 of the following: open-label colesevelam HCl, open label rosiglitazone, or open-label sitagliptin.</brief_summary>
	<brief_title>Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Colesevelam Hydrochloride</mesh_term>
	<criteria>HbA1C 7.0 % to 10.0% on metformin monotherapy; may be withdrawn from other (nonmetformin) drugs if HbA1C is 6.5% to 9.5 % at screening. Subjects currently treated with a thiazolidinedione are excluded.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Colesevelam HCl,</keyword>
	<keyword>rosiglitazone</keyword>
	<keyword>sitagliptin</keyword>
	<keyword>Type 2 diabetes</keyword>
	<keyword>metformin</keyword>
</DOC>